The novel anti-diabetic drug candidate DBPR108 developed in relays by IBPR with the collaborator received the approval to implement Phase I clinical trial from China Food and Drug Administration (CFDA).

IBPR has implemented the project, pre-clinical and clinical trial of the novel anti-diabetic drug candidate DBPR108 and completed the Phase 1 clinical trial of repeated dose at domestic medical centers. In the meantime the cooperator has acquired great progress in promoting the clinical trial in China.
Since China is the primary market of anti-diabetic drugs, the cooperator Genovate Biotechnology had exercised the patent of DBPR108 in China with priority from the end of 2012. Genovate Biotechnology then licensed it to CSPC Pharmaceutical Group Limited (CSPC Pharma) in April 2013 to plan the development of DBPR108 in China cooperatively including the work of pre-clinical trial.
China Food and Drug Administration (CFDA) approved CSPC Pharma to implement the Phase 1 clinical trial in March 2015. This is the first case of novel small-molecule drug in-house developed by NHRI proceeding to the clinical trial in China by the cooperator in relays after completing the Phase 1 clinical trial in Taiwan.

Share Button

Comments are closed.